Cited by 552Treatment of Major DepressionSchizophrenia research and treatmentElectroconvulsive Therapy Studies

Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials

Nelson, J. Craig, Papakostas, George I.·2009·American Journal of Psychiatry

Abstract

OBJECTIVE: The authors sought to determine by meta-analysis the efficacy and tolerability of adjunctive atypical antipsychotic agents in major depressive disorder. METHOD: Searches were conducted of MEDLINE/PubMed (1966 to January 2009), the Cochrane database, abstracts of major psychiatric meetings since 2000, and online trial registries. Manufacturers of atypical antipsychotic agents without online registries were contacted. Trials selected were acute-phase, parallel-group, double-blind controlled trials with random assignment to adjunctive atypical antipsychotic or placebo. Patients had nonpsychotic unipolar major depressive disorder that was resistant to prior antidepressant treatment. Response, remission, and discontinuation rates were either reported or obtained. Data were extracted by one author and checked by the second. Data included study design, number of patients, patient characteristics, methods of establishing treatment resistance, drug doses, duration of the adjunctive trial, depression scale used, response and remission rates, and discontinuation rates for any reason or for adverse events. RESULTS: Sixteen trials with 3,480 patients were pooled using a fixed-effects meta-analysis. Adjunctive atypical antipsychotics were significantly more effective than placebo (response: odds ratio=1.69, 95% CI=1.46-1.95, z=7.00, N=16, p<0.00001; remission: odds ratio=2.00, 95% CI=1.69-2.37, z=8.03, N=16, p<0.00001). Mean odds ratios did not differ among the atypical agents and were not affected by trial duration or method of establishing treatment resistance. Discontinuation rates for adverse events were higher for atypical agents than for placebo (odds ratio=3.91, 95% CI=2.68-5.72, z=7.05, N=15, p<0.00001). CONCLUSIONS: Atypical antipsychotics are effective augmentation agents in major depressive disorder but are associated with an increased risk of discontinuation due to adverse events.

Integrity signals

Registry

Crossref · 10.1176/appi.ajp.2009.09030312

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Nelson, J. C., & Papakostas, G. I.
Affiliations
University of California, San Francisco (US)
Venue
American Journal of Psychiatry
Published
2009-09
Volume
166
Issue
9
Pages
980-991
ISSN
  • 0002-953X (ISSN-L)
  • 1535-7228
OpenAlex
W2104518967
Cited by
552
References
29
Citations by year
2026: 19 · 2025: 17 · 2024: 13 · 2023: 23 · 2022: 27 · 2021: 20 · 2020: 34 · 2019: 23 · 2018: 26 · 2017: 30 · 2016: 45 · 2015: 43 · 2014: 50 · 2013: 60 · 2012: 35
FWCI
3.95
Type
journal article
Language
en
Open access
closed
Locations
  • American Journal of Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Abbott Laboratories
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • Pfizer
  • AstraZeneca
  • GlaxoSmithKline
  • Jazz Pharmaceuticals
  • ACADIA Pharmaceuticals
  • H. Lundbeck A/S
  • Health Resources and Services Administration
  • National Institute of Mental Health
Topics
  • Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
Keywords
atypical antipsychotics, major depressive disorder, antidepressant augmentation, treatment-resistant depression, adjunctive therapy, remission, adverse events, drug tolerability, placebo comparison
MeSH terms
Major Depressive Disorder, Drug Therapy, Combination, Humans, Placebos, Psychiatric Status Rating Scales, Antipsychotic Agents, United States, Randomized Controlled Trials as Topic, MEDLINE, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review